Cancer and cardiovascular disease (CVD) are among the leading causes of morbidity and mortality worldwide. The significant role of epigenetic changes, such as chromatin modifications, DNA and RNA methylations, changes in micro-RNAs, circ-RNA and non-coding RNAs, have been highlighted in the onset and progression of cancer and CVD. The intricate crosstalk between epigenetic mechanisms could also contribute to the development of cancer and CVD. Increasing evidence has recently indicated that the “Sponge effect” of non-coding RNA on miR-29 promotes gastric cancer progression, the negative feedback loop between DNA methylation; micro-RNA silencing tumor-suppressor genes in non-small lung cancer cells; RNA methylation-derived circ-RNA inhibiting the progression of ischemic heart. These findings have generated a growing interest to investigate the underlying mechanisms and provide potential therapy options.
This Research Topic aims to cover the knowledge of recent advancements in epigenetics to cancer and cardiovascular disease development. We expect this knowledge to shed light on how cancer and CVD progression and ultimately enable novel therapies and reduce potential side effects. In addition, we hope this Research Topic will stimulate discussion among the leading scientists in epigenetics and create a compendium to understand cancer and cardiovascular disease development.
We welcome submissions of Original Research, Review, Mini-reviews, Opinions, Methods, and Perspective articles that cover, but are not limited to, the following topics:
•The interaction of epigenetics in cancer progression.
•The interaction of epigenetics in the diagnosis, prognosis and treatment of cancer.
•The interaction of epigenetics in the development of the cardiovascular system.
•The interaction of epigenetics in cardiovascular disease, including hypertension, atherosclerosis, ischemia, remodelling.
Important Note: All contributions to this Research Topic must be involved at least two epigenetics processes, as defined in their mission statements.
Cancer and cardiovascular disease (CVD) are among the leading causes of morbidity and mortality worldwide. The significant role of epigenetic changes, such as chromatin modifications, DNA and RNA methylations, changes in micro-RNAs, circ-RNA and non-coding RNAs, have been highlighted in the onset and progression of cancer and CVD. The intricate crosstalk between epigenetic mechanisms could also contribute to the development of cancer and CVD. Increasing evidence has recently indicated that the “Sponge effect” of non-coding RNA on miR-29 promotes gastric cancer progression, the negative feedback loop between DNA methylation; micro-RNA silencing tumor-suppressor genes in non-small lung cancer cells; RNA methylation-derived circ-RNA inhibiting the progression of ischemic heart. These findings have generated a growing interest to investigate the underlying mechanisms and provide potential therapy options.
This Research Topic aims to cover the knowledge of recent advancements in epigenetics to cancer and cardiovascular disease development. We expect this knowledge to shed light on how cancer and CVD progression and ultimately enable novel therapies and reduce potential side effects. In addition, we hope this Research Topic will stimulate discussion among the leading scientists in epigenetics and create a compendium to understand cancer and cardiovascular disease development.
We welcome submissions of Original Research, Review, Mini-reviews, Opinions, Methods, and Perspective articles that cover, but are not limited to, the following topics:
•The interaction of epigenetics in cancer progression.
•The interaction of epigenetics in the diagnosis, prognosis and treatment of cancer.
•The interaction of epigenetics in the development of the cardiovascular system.
•The interaction of epigenetics in cardiovascular disease, including hypertension, atherosclerosis, ischemia, remodelling.
Important Note: All contributions to this Research Topic must be involved at least two epigenetics processes, as defined in their mission statements.
